As a single agent or in combination for: • The first line treatment of stage 3 or 4 non small cell lung cancer. • The treatment of advanced breast cancer stage 3 and 4 relapsing after or refractory to an anthracycline containing regimen.
• As a single agent or in combination for the first line treatment of stage 3 or 4 non-small cell lung cancer. • Treatment of advanced breast cancer stage 3 and 4 relapsing after or refractory to an anthracycline containing regimen.
Vinorelbine is indicated in adults in the treatment of: - As a single agent in patients with metastatic breast cancer (stage 4) in which chemotherapy with anthracycline and taxane has failed or is inadequate. - Non-small cell lung cancer (stage 3 or 4).